Legacy Capital Group California Inc. Acquires New Position in Biogen Inc. $BIIB

Posted by on Jul 15th, 2026

Legacy Capital Group California Inc. bought a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 2,901 shares of the biotechnology company’s stock, valued at approximately $532,000.

Several other large investors also recently bought and sold shares of BIIB. Empowered Funds LLC increased its stake in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Biogen by 172.2% during the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of Biogen during the second quarter valued at $216,000. Cerity Partners LLC grew its holdings in shares of Biogen by 15.3% during the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after buying an additional 6,184 shares during the last quarter. Finally, NewEdge Advisors LLC increased its position in shares of Biogen by 13.4% in the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 316 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Biogen stock opened at $191.95 on Wednesday. The stock has a market capitalization of $28.34 billion, a P/E ratio of 20.60 and a beta of 0.16. The company’s fifty day moving average price is $198.70 and its 200 day moving average price is $188.51. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $219.72.

Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the business posted $3.02 earnings per share. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 13.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and boosted their price target for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Finally, Sanford C. Bernstein decreased their price objective on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $220.04.

View Our Latest Stock Report on Biogen

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

  • Positive Sentiment: Biogen and Eisai won FDA approval for LEQEMBI IQLIK, expanding LEQEMBI into an at-home initiation option that could improve treatment convenience and support future sales. Article Title
  • Positive Sentiment: Needham reiterated a Buy rating and a $256 price target, citing continued confidence in diranersen after the CELIA data presentation. Article Title

Biogen Company Profile

(Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Featured Articles

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.